D. Boral Capital Reaffirms Buy Rating for CervoMed (NASDAQ:CRVO)

D. Boral Capital restated their buy rating on shares of CervoMed (NASDAQ:CRVO) in a report published on Wednesday,Benzinga reports. D. Boral Capital currently has a $10.00 target price on the stock.

Several other research firms have also weighed in on CRVO. Roth Capital raised CervoMed to a “strong-buy” rating in a research report on Thursday, December 5th. Morgan Stanley reissued an “underweight” rating on shares of CervoMed in a research report on Wednesday, December 11th. Brookline Capital Management raised shares of CervoMed from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 11th. HC Wainwright downgraded shares of CervoMed from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 17th. Finally, Jones Trading upgraded shares of CervoMed from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Thursday, March 13th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, CervoMed has an average rating of “Moderate Buy” and a consensus price target of $27.50.

CervoMed Price Performance

Shares of CRVO opened at $7.71 on Wednesday. The company has a 50-day moving average of $3.72 and a two-hundred day moving average of $7.68. The stock has a market cap of $67.10 million, a price-to-earnings ratio of -3.80 and a beta of 1.84. CervoMed has a one year low of $1.80 and a one year high of $25.92.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%. The firm had revenue of $2.16 million during the quarter, compared to analyst estimates of $1.51 million. Analysts anticipate that CervoMed will post -1.88 earnings per share for the current year.

Institutional Investors Weigh In On CervoMed

Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC acquired a new stake in CervoMed in the 3rd quarter worth approximately $56,000. Barclays PLC lifted its stake in shares of CervoMed by 323.6% in the third quarter. Barclays PLC now owns 7,748 shares of the company’s stock worth $113,000 after buying an additional 5,919 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of CervoMed during the 4th quarter worth $26,000. DRW Securities LLC acquired a new position in CervoMed in the 4th quarter valued at $30,000. Finally, Mariner LLC bought a new position in CervoMed in the 4th quarter worth $30,000. Institutional investors and hedge funds own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.